All posts by admin

MediPharm Labs Closes Previously Announced Bought Deal Equity Financing

MediPharm Labs Closes Previously Announced Bought Deal Equity Financing

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the closing of its previously announced “bought deal” offering of units of the Company (the “Units”) for total gross proceeds of $33,350,000. The Company sold 57,500,000 Units at a price of $0.58 per Unit, including 7,500,000 Units sold pursuant to the exercise of the underwriters’ over-allotment option in full at closing. The offering was led by Cantor Fitzgerald Canada Corporation, as lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters that included BMO Nesbitt Burns Inc., Canaccord Genuity Corp. and Stifel Nicolaus Canada Inc. Alliance Global Partners acted as a financial advisor in connection with the offering.

Each Unit is comprised of one common share in the capital of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant shall be exercisable to acquire one Share at an exercise price of $0.70 per Share for a period of 24 months from the date hereof.

Net proceeds from the offering are intended to fund growth of the Company’s Cannabis 2.0 product portfolio, expand medical products and Active Pharmaceutical Ingredient portfolio for export, pharmaceutical registrations, research and development related to clinical trial formulations, sales and marketing in new markets and for general corporate purposes, including funding working capital.

“In addition to the strong progress we have made in the medical, wellness and adult use markets in Canada, Australia, Germany and Latin America, last month we received our key Cannabis Drug Licence,” said Keith Strachan, President and Interim Chief Executive Officer, MediPharm Labs. “This licence, among others, combined with our global GMP platform greatly increases our opportunities with pharma companies to produce existing approved cannabis drugs or develop and manufacture innovative drugs through later stage clinical trials – all which we expect to enhance our future growth.”

Strachan added, “This financing demonstrates the confidence investors have placed in our platform, our people and our potential in an emerging global pharmaceutical cannabis industry. We are pleased with the strong support from our long-term investors that were part of an approximate $7 million president’s list, which included the participation of four independent directors.”

In connection with the offering, the Company filed a final short form base shelf prospectus in each of the provinces of Canada, other than Québec (the “Base Shelf Prospectus”) dated February 24, 2021 and a prospectus supplement to the Base Shelf Prospectus dated March 2¸2021 (the “Prospectus Supplement”) in each of the provinces of Canada other than Quebec, which will be used in connection with the offering.

Copies of the Prospectus Supplement and the Base Shelf Prospectus are available on SEDAR at www.sedar.com and may also be obtained from Cantor Fitzgerald Canada Corporation, 181 University Avenue, Suite 1500, Toronto, ON, M5H 3M7.

No securities regulatory authority has either approved or disapproved the contents of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The Units, the Shares, the Warrants and the Shares issuable on exercise of the Warrants have not been and will not be registered under the U.S. Securities Act, or any state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, “U.S. persons” (as defined in the U.S. Securities Act) absent registration or an applicable exemption from such registration requirements.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, they formulate, consumer-test, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its wholly-owned Australian extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: growth of the Company’s Cannabis 2.0 product portfolio; an expanded medical products and Active Pharmaceutical Ingredients portfolio for export; pharmaceutical registrations; research and development related to clinical trial formulations; sales and marketing in new markets; increased opportunities with pharma companies to produce existing approved cannabis drugs or develop and manufacture innovative drugs through later stage clinical trials; enhanced future growth; and the Company’s expected use of proceeds from the offering. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.


Primary Logo

Published at Fri, 05 Mar 2021 14:06:36 +0000

Cresco Labs (CRLBF )to Report Fourth Quarter and Full Year 2020 Financial Results on March 25th, 2021

Cresco Labs (CRLBF )to Report Fourth Quarter and Full Year 2020 Financial Results on March 25th, 2021




Cresco Labs (CRLBF )to Report Fourth Quarter and Full Year 2020 Financial Results on March 25th, 2021 | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™
























Published at Thu, 04 Mar 2021 14:00:07 +0000

Namaste Technologies Announces Appointment of New CFO

Namaste Technologies Announces Appointment of New CFO

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, is pleased to announce the appointment of Ms. Slava Klems, CPA, CA as Chief Financial Officer (CFO) effective March 3, 2021. Ms. Klems has been the Interim CFO as of October 31, 2020.

“I would like to congratulate Ms. Klems on her well deserved appointment,” said Meni Morim, CEO of Namaste. “Ms. Klems has an impressive background in corporate finance with experience in technology and platform integration and has shown an incredible business acumen since joining the Company. Since Ms. Klems tenure, much work has been done to automate many new areas in accounting including our accounts payable cycle, streamlining the payment processing system directly to our bank accounts and managing our monthly budgeting analysis by integrating the company’s budgets directly into the accounting system. I look forward to continue working with Ms. Klems as we seek to drive Namaste forward.”

About Slava Klems

Ms. Klems is an accomplished finance executive with over 10 years experience in senior finance management positions at AIMIA Inc. (Aeroplan) and Dominion Citrus Income Fund, plus experience across diverse industries including retail, distribution, manufacturing, pharmaceutical and automotive sectors. She joined Namaste in July 2020 and has proven herself as a driven and hardworking professional with a proven record in change management, process optimization and improved operational efficiencies. Ms. Klems has also successfully completed multiple ERP software implementation projects, including PeopleSoft and Workday to integrate Operations and Finance functions driving sustainable operational effectiveness. Ms. Klems holds a Master of Science and a Bachelor of Business Administration from York University and earned her Chartered Accountant designation with KPMG.

Corporate Update – Engagement of Stonebridge Partners LLC

The Company announced it has engaged the services of Stonebridge Partners LLC (Technical420) to provide investor relations activities (as defined in TSX Venture Exchange policy). Stonebridge Partners, LLC has been engaged in a three-month contract to enhance investor relations efforts and provides content marketing services for a monthly fee of $6,000 USD. Further information may be found at: https://technical420.com/

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@namastetechnologies.com

Source: Namaste Technologies Inc.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Thu, 04 Mar 2021 11:59:41 +0000

Who Is Going To Win The North American Cannabis Arms Between The Canadian Licensed Producers and U.S. Multi-State Operators?

Who Is Going To Win The North American Cannabis Arms Between The Canadian Licensed Producers and U.S. Multi-State Operators?

For years, we have been highlighting the growth of the US cannabis market and continue to view it as a more attractive investment opportunity when compared to the Canadian market.

During the last year, US cannabis operators have reported explosive growth, and this has caught the attention of several large scale Canadian Licensed Producers (LPs). In an attempt to remain relevant in an industry that is rapidly advancing, several Canadian LPs have acquired strategic US assets to have leverage to the market once Federal legislation changes.

Companies like Canopy Growth Corp. (WEED.TO) and Aphria, Inc. (APHA.TO) (APHA) own strategic US assets that will allow for the operators to capitalize on the market as soon as regulations change. Tilray Inc. (TLRY) also has leverage to the US market via its planned mega-merger with Aphria.

We believe that the Canadian cannabis companies that are unable to create a presence in the U.S. are going to face long-term challenges and we want our readers to be aware of our thesis. Based on data from Statistica Canada, Cowen and Company, Bank of America, Stifel, BMO, Leafly, Business Insider and Sammy J Estimates, the US cannabis market greatly outperformed the Canadian cannabis market, and this is a trend that we expect to become more pronounced.

Based on the data from these firms, analysts determined that US multi-state-operators (MSOs) will trade at a 6x multiple for enterprise value/revenues in 2022. This is substantially lower than the multiple that was determined for Canadian LPs. According to the data, Canadian LPs are expected to trade at a 13x multiple for enterprise value/revenues in 2022.

When you analyze the projected 2022 enterprise value/EBITDA for US MSOs and Canadian LPs, the differential is significant. In 2022, US MSOs are expected to trade at 17x multiple while Canadian LPs are expected to trade at 83x multiple. We believe these metrics cannot be ignored and have a higher conviction level in the US cannabis industry over the long-term.

One of the most interesting pieces of data that we have come across when comparing the US and the Canadian cannabis industries is related to the market capitalizations of the 5 largest operators in each region. The 5 largest MSOs have a combined market capitalization that is similar to the combined market capitalizations of the 5 largest Canadian LPs. We expect to see the US market to exceed the size of the US cannabis market in 2021 and expect US operators to see multiple expansion when cannabis is legalized at the federal level.

Once cannabis is legalized in the US, we expect large MSOs take a look at the opportunity in the European Union (EU). Currently, Canadian LPs have been the main beneficiary of the growth of the EU cannabis market, and we expect this to change once the laws change in the US.

If you are interested in learning about the Canadian companies that are focused on the US market, please send an email to support@technical420.com with the subject “LPs that are Levered to the US Cannabis Market” to be added to our distribution list.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Thu, 04 Mar 2021 12:42:04 +0000

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
This potential treatment opportunity was confirmed by the company’s bioinformatics platform, PsyCollage

VANCOUVER, BC, Mar. 04, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company’s bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain trauma.

Ibogaine is a psychoactive substance extracted from the iboga shrub native to West Africa. Contributing to its powerful anti-addiction actions, ibogaine is associated with increases in the levels of brain neurotrophic factors, particularly GDNF and BDNF, which have potent neuroregenerative and neuroprotective properties.1 Ibogaine is thought to repair and reset the brain’s reward system, facilitating detoxification in the context of addiction. In addition, it may stimulate the growth of new dopamine neurons, which further supports its therapeutic potential for neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease.1

For these reasons, MINDCURE is synthesizing ibogaine, as announced in a news release dated March 3, 2021, to be used in the Company’s preclinical and clinical trials. Recently, the Company’s PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.

“PsyCollage ensures we are moving in the right direction in our mission to provide alternative and effective treatment options for psychological and physiological pain,” said Kelsey Ramsden, President & CEO, MINDCURE. “Ibogaine has centuries of therapeutic history reinforcing its potential to heal pain. As one of the first companies to manufacture synthetic ibogaine, we’re confident our research and development teams can help contribute to the drug’s uses and develop protocols that ultimately progress healing in Canada and around the world.”

Ibogaine has been used by West African communities for centuries in rituals and healing ceremonies. It was first introduced to the western world in 1864, and later marketed in France as a “neuromuscular stimulant” to combat fatigue, depression, and infectious disease between 1939-1970.2 The U.S. made possession of ibogaine illegal in 1967, and the U.S. FDA classified ibogaine as a schedule I drug in 1970, along with psilocybin and LSD. In Canada, Ibogaine was unregulated until 2017 when Health Canada added it to the Prescription Drug List, severely limiting legal access; however, more recently, the regulatory landscape is again becoming more favourable.

“Ibogaine’s therapeutic potential isn’t a new concept. MINDCURE’s bioinformatics platform, PsyCollage, however, gives us a starting point and a plethora of research to continue guiding us as we investigate ibogaine’s regenerative potential for healing, with a primary focus on brain trauma and neuropathic pain,” said Ryan Hartwell, Chief Scientific Officer, MINDCURE.

About PsyCollage

PsyCollage is MINDCURE’s proprietary bioinformatics platform used to direct MINDCURE’s research team in product discovery activities and decision-making. PsyCollage works by compiling predictive correlative statistical analytics from decades of documented clinical research. PsyCollage has developed into a turnkey resource for discovering target receptors and methods, managing clinical trial data, and mapping strategic business partnerships.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the opportunities for ibogaine to support neuroregenerative pathways that MINDCURE believes could be pivotal in treating neuropathic pain and brain trauma; MINDCURE synthesizing ibogaine to be used in the Company’s preclinical and clinical trials; Ibogaine repairing and resetting the brain’s reward system, facilitating detoxification in the context of addiction, stimulating the growth of new dopamine neurons, and supporting neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease; MINDCURE’s mission to provide alternative and effective treatment options for psychological and physiological pain; MINDCURE becoming one of the first companies to manufacture synthetic ibogaine, and contributing to the drug’s uses and develop protocols that ultimately progress healing in Canada and around the world.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; ibogaine’s ability to address neuropathic pain, neuroregeneration, and brain trauama will help MINDCURE achieve its research and business goals; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; ibogaine’s ability to address neuropathic pain, neuroregeneration, and brain trauama will not help MINDCURE achieve its research and business goals; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995

Jonathan L. Robinson CFA
Partner
Oak Hill Financial Inc.
jrobinson@oakhillfinancial.ca
416-669-1001

[1] Soledad Marton et al., “Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits,” Frontiers in Pharmacology 10 (May 2019), https://doi.org/10.3389/fphar.2019.00193.

[2] Thomas Brown, “Ibogaine in the Treatment of Substance Dependence,” Current Drug Abuse Reviews 6, no. 1 (May 1, 2013): pp. 3, https://doi.org/10.2174/15672050113109990001.

SOURCE: https://www.newswire.ca/news-releases/mindcure-discovers-potential-opportunity-for-ibogaine-assisted-psychotherapy-to-treat-neuropathic-pain-and-traumatic-brain-injury-871573661.html
 

Disclosure: Mind Cure is a client of Psychedelic Stock Watch

Published at Thu, 04 Mar 2021 09:25:20 +0000

Luka Dončić Joins Team BioSteel as Global Chief Hydration Officer

Luka Dončić Joins Team BioSteel as Global Chief Hydration Officer

BioSteel today announced a historic long-term global partnership between the sports hydration company and all-star basketball player, Luka Dončić. Dončić has been appointed the title of Global Chief Hydration Officer. The partnership with BioSteel makes Dončić the latest addition to the brand’s impressive athlete roster including Patrick Mahomes.

‘I’m excited to work with BioSteel as Global Chief Hydration Officer because I am passionate about the importance of healthy hydration on and off the court,’ says Dončić. ‘This partnership is a great opportunity for me to teach today’s youth about the importance of clean, healthy hydration using BioSteel’s sports drinks.’

‘It’s important to us that our partnerships are authentic as we continue to grow our brand,’ says Michael Cammalleri, Co-Founder and Co-CEO. ‘As the Official Sports Drink of the Dallas Mavericks, Luka has been hydrating with BioSteel’s zero sugar sports drink for the entire season. We’re thrilled to announce a new partnership with Luka, who believes in our product, to amplify our story and accelerate our growth.’

Dončić joins a growing list of top tier athletes and ambassadors, which reflect the company’s roots of working with those who were consumers of the brand prior to being formally endorsed by BioSteel. As a member of Team BioSteel, Dončić will extend the brand’s footprint by reaching new health-conscious consumers and aspiring athletes.

Off the court, Dončić is passionate about his philanthropic endeavors, having recently donated to the Dallas Mayor’s Fund for Dallas winter storm relief. He is an avid gamer, is a fan of anime and can speak four languages fluently.

BioSteel is expanding in the U.S. market at a rapid pace, securing the country’s top grocery, mass, gas and convenience retailers, with direct distribution partners across the country to support this growth.

BioSteel’s environmentally-friendly sports drink with zero sugar can be purchased at BioSteel.com.

About BioSteel

BioSteel is a North American operated sports hydration company that was built on the mandate of providing the safest, healthiest, and most effective line of nutritional products available. BioSteel’s line includes a range of nutritional products including sports drinks, proteins, and everyday essentials. BioSteel products are currently readily available across North America, and globally with select retail partners or direct to consumers online, through www.biosteel.com.

SOURCE BioSteel Sports Nutrition Inc.

For further information: Lindsey Soper, Communications Manager, BioSteel Sports Nutrition Inc., 647-537-9512, lsoper@biosteel.com

Any enquiries regarding Luka Doncic please email Hollie@sisoagency.com

Attachments

Disclaimer

Canopy Growth Corp. published this content on 03 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 March 2021 14:38:50 UTC

(C) Copyright 2021 – Canopy Growth Corp.

Keywords: Canopy-Growth-Corp.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Wed, 03 Mar 2021 14:49:47 +0000

Time to load up on Square Inc (NYSE:SQ)

Time to load up on Square Inc (NYSE:SQ)

The tech stocks sold off due to rising rate fears. However, U.S. stock futures rose sharply in early morning trading on Monday, as Treasury yields retreated from their highs from last week, easing concerns about inflation and that higher rates would undermine equity valuations. Investors have a “rare” opportunity to buy the dip here, according to Mizuho analyst Dan Dolev.

The mobile payment company is coming off mixed fourth-quarter results earlier this week where the company revealed it purchased $170 billion worth of Bitcoin.

Shares finished the week down almost 17% but Dolev believes Square is in good shape for the long run.

The company’s bitcoin-enabled Cash App is “holding up well” and should continue to see growth after some recent deceleration, he wrote. The app allows users to transfer money via a mobile phone app.

“We see overall Seller & Cash App gross profit accelerating in 1Q21,” he said.

And according to Dolev, the company’s products are “highly levered” to any government stimulus if more should transpire as is expected.

“Following the stimulus in March 2020, Cash App gross profit growth accelerated,” Dolev said.

The firm also has a Street high price target of $380 per share and even though the stock sold off this week, Square’s momentum remains firmly well-positioned, he said.

Source: https://www.cnbc.com/

Published at Mon, 01 Mar 2021 14:02:02 +0000

Best Marijuana Stocks For March 2021? 2 Cannabis Stocks That Could See Gains

Best Marijuana Stocks For March 2021? 2 Cannabis Stocks That Could See Gains




Best Marijuana Stocks For March 2021? 2 Cannabis Stocks That Could See Gains | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

























Published at Mon, 01 Mar 2021 15:10:07 +0000

Namaste Technologies Announces CannMart.com is LIVE in the USA

Namaste Technologies Announces CannMart.com is LIVE in the USA

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, is pleased to announce that www.CannMart.com is live in the USA offering Americans hemp derived CBD and smoking accessories. Namaste is excited to be leveraging its VendorLink technology in collaboration initially with DankStop and PeakBirch Logic, Inc., and looks forward to adding more partners to the platform.

The announcement of this expansion in the USA underscores Namaste’s intention to increase its total addressable market and exploration into other verticals and geographies as regulation evolves and other adjacent complementary market opportunities present themselves.

“With ever stronger signals that the regulatory landscape in the USA is evolving, our entry into the jurisdiction through the sale of hemp derived CBD and accessories will position us strategically to begin capturing new market share and build a first mover advantage if and when cannabis becomes legalized federally,” said Meni Morim, CEO of Namaste. “This development also further validates our investment in technology, as the expansion will be facilitated via our marketplace technology. We look forward to building on this positive momentum as we continue to execute our strategy to position Namaste as a leading global cannabis and wellness company.”

“Our goal will be to aggressively expand our footprint into the USA as we scale up our marketplace platform,” said Chad Agate, CTO and VP of Marketplace at Namaste. “We are not growing or exporting products from Canada into the USA, we are simply carving out our role as the facilitators using CannMart.com and our VendorLink platform. American and other companies that wish to sell legal products in the USA can now use our innovative platform to conduct business similarly to Amazon. We look forward to adding more partners selling their innovative products throughout the USA.”

For companies looking to expand their presence on our marketplace platform please contact us via the following link: https://cannmart.com/sell-on-cannmart

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

About DankStop

DankStop is the one of the world’s largest and fastest growing online smoking supply retailers. Nothing like your ordinary headshop, DankStop is the quickest, cheapest, and easiest way to get the best smoking supplies delivered discreetly to your door. With an industry leading and innovative website, dedicated support team, and the biggest product selection available online, DankStop has single-handedly raised the bar for the online smoking supply industry since 2014. From humble beginnings, our co-founders started DankStop in “moms basement”​. Our founding vision was to remove the “sketchy”​ stigma from the headshop industry by providing high quality, low priced products in a simple and transparent manner. Leveraging our in house technology, we now offer a variety of B2B services for the Cannabis industry in addition to our retail websites ranging from drop shipping to third party logistics. Information on the Company and its many products can be accessed through: www.dankstop.com

About PeakBirch Logic, Inc.

PeakBirch is a cohesive ecommerce technology group scaling multiple online businesses to become internationally successful brands. With a strong focus on consumer journey, deep analytics and AI powered trend analysis PeakBirch unlocks the true growth potential of customer-centric brands by providing revenue acceleration with customer experience optimization via a lean platform. Through a combination of the latest digital best practices and a proven team, PeakBirch Logic is committed to generating significant and sustained return on investor capital over the long-term.

Information on the Company can be accessed through: www.peakbirch.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@namastetechnologies.com

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen. The forward-looking information contained herein, including, without limitation, statements related to Namaste’s entry into the United States markets for smoking accessories and hemp-derived CBD via CannMart.com,, Namaste’s ability to leverage its VendorLink technology in collaboration with DankStop and PeakBirch Logic, Inc., Namaste’s proposed expansion efforts, and the likelihood of legislative change in the United States. Such statements are made as of the date of this press release and are based on assumptions that management believed to be reasonable at the time, including, without limitation, Namaste’s ability to ensure compliance with applicable state and federal laws with respect to the sale of smoking accessories and hemp-derived CBD in the United States, Namaste’s ability to leverage its VendorLink technology in collaboration with DankStop and PeakBirch Logic, Inc., anticipated continued improvements to the regulatory landscape for the sale of cannabis, associated products and accessories that will benefit Namaste’s business in the United States and globally, Namaste’s beliefs regarding the expected demand in the future for cannabis products and current demand for accessories and hemp derived CBD products and the expected growth of these market globally, results of operations, operational matters, historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the failure to achieve the intended sales results and benefits from the Company’s expansion efforts, regulatory risk both in the United States and globally, including in particular regulations not evolving in a manner to that would benefit Namaste’s business, risks relating to the Company’s ability to execute its business strategy and plans and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 26 Feb 2021 15:12:30 +0000